GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » U2Bio Co Ltd (XKRX:221800) » Definitions » Change In Payables And Accrued Expense

U2Bio Co (XKRX:221800) Change In Payables And Accrued Expense : ₩0 Mil (TTM As of Jun. 2024)


View and export this data going back to 2015. Start your Free Trial

What is U2Bio Co Change In Payables And Accrued Expense?

U2Bio Co's Change In Payables And Accrued Expense for the quarter that ended in Jun. 2024 was ₩0 Mil. It means U2Bio Co's Accounts Payable & Accrued Expense stayed the same from Mar. 2024 to Jun. 2024 .

U2Bio Co's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was ₩0 Mil. It means U2Bio Co's Accounts Payable & Accrued Expense stayed the same from Dec. 2022 to Dec. 2023 .

U2Bio Co Change In Payables And Accrued Expense Historical Data

The historical data trend for U2Bio Co's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

U2Bio Co Change In Payables And Accrued Expense Chart

U2Bio Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Payables And Accrued Expense
Get a 7-Day Free Trial Premium Member Only - - - - -

U2Bio Co Quarterly Data
Jun22 Mar23 Jun23 Mar24 Jun24
Change In Payables And Accrued Expense - - - - -

U2Bio Co Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

U2Bio Co Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of U2Bio Co's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

U2Bio Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » U2Bio Co Ltd (XKRX:221800) » Definitions » Change In Payables And Accrued Expense
Comparable Companies
XKRX:031860 XKRX:347740 XKRX:245620 XKRX:086040 XKRX:229000 XKRX:253840 XKRX:122310 XKRX:363250 XKRX:950200 XKRX:109820 TMO DHR SHSE:603259 IDXX IQV A XSWX:LONN MTD ICLR ILMN
Traded in Other Exchanges
N/A
Address
Basement 1, 68 Gumaro Songpagu, Seoul, KOR
Website
http://www.u2bio.co.kr
U2Bio Co Ltd provides vitro diagnostic test services. The company is engaged in offering general diagnostic tests, molecular diagnostic tests, and breastfeeding nutritional analysis services among others.

U2Bio Co Headlines

No Headlines